Esketamine for reducing perioperative opioid use in laparoscopic colorectal cancer surgery: impact on postoperative nausea and vomiting at 48 hours

Effect of esketamine-based opioid reduction anesthesia on postoperative nausea and vomiting in patients undergoing laparoscopic radical resection of colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN25778550

Enrollment

Registered

2024-09-26

Start date

2023-10-01

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting Digestive System

Interventions

Participants will be randomly divided into two groups, the esketamine group (Group K) and the control group (Group C). The drugs required for anesthesia induction will be formulated according to the d

Group C Sufentanil 2 µg/kg, palonosetron hydrochloride 0.25mg, diluted to 100ml with normal saline. The intravenous analgesia pumps in both groups were set as f

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing laparoscopic radical resection of colorectal cancer 2. Aged 18-80 years old, no gender limitation 3. ASA I-III 4. Postoperative agreed to use the PCIA 5. Voluntarily signed informed consent

Exclusion criteria

Exclusion criteria: 1. People with severe consciousness disorder or mental system disease and cognitive dysfunction 2. Merge heart liver and kidney and other viscera function disorder 3. Arrhythmia (atrial fibrillation or atrioventricular conduction block between arrhythmia etc.) or after cardiac pacemaker implantation 4. BP or 180/100 MMHG, untreated or poor control of blood pressure 5. Increased intracranial pressure 6. Glaucoma 7. Without treatment, and treatment of hyperthyroidism 8. Known for esketamine injection, the active ingredient or complementary makings allergies 9. Alcohol or alcohol addiction 10. Have a vision, hearing, or language barrier and cannot communicate and cooperate

Design outcomes

Primary

Measure	Time frame
The occurrence and intensity of postoperative nausea and vomiting (PONV) measured using the PONV Impact Scale at 1, 24, and 48 h after surgery	—

Secondary

Measure	Time frame
1. The intraoperative dosage of opiates and propofol measured using data recorded in patient medical records throughout the procedure 2. Blood pressure, heart rate, bispectral index (BIS) value and surgical pleth index (SPI) value measured using data recorded in patient medical records collected before the operation, immediately after intubation, pneumoperitoneum establishment, 0.5h during operation, 1h during operation, 1.5h during operation, and at the end of the operation 3. Serum IL-6, IL-10, TNF-a, gastrin, motilin and substance P levels measured using ELISA in venous blood collected from patients in T0 (before surgery), T1 (1h during surgery), T2 (1h after surgery), T3 (24h after surgery) and T5 (72h after surgery) 4. The quality of postoperative recovery measured using the recovery scale QoR-15 before and 48 hours after surgery 5. Pain level at rest and exercise measured using a visual analog scale (VAS) at 1h, 24h and 48h after surgery 6. Dizziness, diplopia, hallucination or nightmare and other adverse reactions measured using data collected in patient medical records at 1 h, 24 h and 48 h after surgery	—

Measure

Time frame

1. The intraoperative dosage of opiates and propofol measured using data recorded in patient medical records throughout the procedure 2. Blood pressure, heart rate, bispectral index (BIS) value and surgical pleth index (SPI) value measured using data recorded in patient medical records collected before the operation, immediately after intubation, pneumoperitoneum establishment, 0.5h during operation, 1h during operation, 1.5h during operation, and at the end of the operation 3. Serum IL-6, IL-10, TNF-a, gastrin, motilin and substance P levels measured using ELISA in venous blood collected from patients in T0 (before surgery), T1 (1h during surgery), T2 (1h after surgery), T3 (24h after surgery) and T5 (72h after surgery) 4. The quality of postoperative recovery measured using the recovery scale QoR-15 before and 48 hours after surgery 5. Pain level at rest and exercise measured using a visual analog scale (VAS) at 1h, 24h and 48h after surgery 6. Dizziness, diplopia, hallucination or nightmare and other adverse reactions measured using data collected in patient medical records at 1 h, 24 h and 48 h after surgery

—

Countries

China

Contacts

Public ContactZhao Xin

644388187@qq.com+86 13775127431

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026